Clinical trial · Interventional
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
Phase II Study of Treatment Selection Based Upon Tumor Thymidylate Synthase Expression in Previously Untreated Patients With Metastatic Colorectal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, irinotecan, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of colorectal cancer by blocking blood flow to the tumor. Giving bevacizumab together with combination chemotherapy may be a better way to block tumor growth. Studying the amount of an enzyme found in the tumor may help doctors plan the best treatment. PURPOSE: This randomized phase II trial is studying giving bevacizumab, oxaliplatin, and irinotecan or giving bevacizumab, oxaliplatin, leucovorin, and fluorouracil in treating patients with metastatic or recurrent colorectal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| bevacizumab | Biological | Bevacizumab | ALIAS |
| fluorouracil | Drug | Fluorouracil | ALIAS |
| irinotecan hydrochloride | Drug | Irinotecan | ALIAS |
| leucovorin calcium | Drug | Leucovorin | ALIAS |
| Oxaliplatin | Drug | Oxaliplatin | ALIAS |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Arm A (High TS, IROX/bev)
- description
- Patients with high TS who are randomized to Arm A receive irinotecan and oxaliplatin plus bevacizumab (IROX/bev). The combination regimen is administered by giving bevacizumab IV over 30-90 minutes followed by oxaliplatin IV over 2 hours and irinotecan IV over 90 minutes on days 1 and 15 every 28 days until disease progression or until any criterion specified in protocol is met.
- interventionNames
- Biological: bevacizumab
- Drug: irinotecan hydrochloride
- Drug: Oxaliplatin
- type
- EXPERIMENTAL
- label
- Arm B (High TS, FOLFOX/bev)
- description
- Patients with high TS who are randomized to Arm B receive 5-Fluorouracil, leucovorin, oxaliplatin, and bevacizumab (FOLFOX/bev). The combination regimen is administered by giving bevacizumab and oxaliplatin as in Arm A, leucovorin calcium IV over 2 hours, and fluorouracil IV over 5 minutes and then continuously over 46 hours on days 1 and 15 every 28 days until disease progression or until any criterion specified in protocol is met.
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
INCLUSION: * Metastatic or locally recurrent colorectal adenocarcinoma * Measurable disease * At least 2 formalin-fixed paraffin embedded core needle biopsies OR fine needle aspirate containing a minimum of 3 clusters of malignant cells and fixed tissue from the previous biopsy * If no tissue samples are available the patient must be willing to undergo biopsy of a metastatic site * Age 18 and over * Eastern Cooperative Oncology Group (ECOG) Performance status 0-2 * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Prothrombin time (PT)/international normalized ratio (INR) ≤ 1.5 unless patient is receiving full-dose anticoagulants AND the following criteria are met: * In-range INR (usually between 2 and 3) AND on a stable dose of warfarin or low molecular weight heparin * No active bleeding or pathological condition that is associated with a high risk of bleeding * Partial thromboplastin time (PTT) \< 1.5 times upper limit of normal (ULN) * Alanine transaminase (ALT) and aspartate aminotransferase (AST) \< 3 times ULN * Bilirubin ≤ 1.5 times ULN * Creatinine ≤ 1.8 mg/dL * Meets 1 of the following criteria: * Protein negative on urine dipstick * Urine protein/creatinine ratio \< 1.0 * Less than 2 g protein on 24-hour urine collection * Patients with a history of hypertension must meet the following criteria: * Blood pressure \< 150/90 mm Hg * Stable regimen of anti-hypertensive therapy * More than 28 days since prior major or open surgery * Negative pregnancy test * Fertile patients must use effective contraception during and for 3 months after study participation * Prior non-colorectal malignancies are allowed provided the following criteria are met: * No current clinical evidence of persistent or recurrent disease * No active therapy for non-colorectal malignancy, including hormonal therapy EXCLUSION: * Pregnant or nursing * Arterial thromboembolic events within the past 6 months, including the following: * Transient ischemic attack * Cerebrovascular accident * Unstable angina pectoris * Myocardial infarction * Symptomatic arrhythmia * Symptomatic congestive heart failure * Clinically significant peripheral artery disease * New York Heart Association class III or IV heart disease * Serious nonhealing wound, ulcer, or bone fracture within the past 28 days * Significant traumatic injury within the past 28 days * Neuropathy ≥ grade 2 * Ongoing or active infection * Concurrent prophylactic filgrastim (G-CSF) or sargramostim (GM-CSF) * Prior chemotherapy for metastatic disease. Adjuvant therapy completed at least 12 months before first evidence of metastasis allowed * Cardiovascular, renal, hepatic, or other nonmalignant systemic disease that would preclude study therapy
References
Publications (0)
Data not yet available